CA3064567A1 - A protein binding nkg2d, cd16 and a tumor-associated antigen - Google Patents

A protein binding nkg2d, cd16 and a tumor-associated antigen Download PDF

Info

Publication number
CA3064567A1
CA3064567A1 CA3064567A CA3064567A CA3064567A1 CA 3064567 A1 CA3064567 A1 CA 3064567A1 CA 3064567 A CA3064567 A CA 3064567A CA 3064567 A CA3064567 A CA 3064567A CA 3064567 A1 CA3064567 A1 CA 3064567A1
Authority
CA
Canada
Prior art keywords
seq
antigen
chain variable
binding site
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3064567A
Other languages
English (en)
French (fr)
Inventor
Gregory P. CHANG
Ann F. CHEUNG
William Haney
Bradley M. LUNDE
Bianka Prinz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dragonfly Therapeutics LLC
Original Assignee
Dragonfly Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics LLC filed Critical Dragonfly Therapeutics LLC
Publication of CA3064567A1 publication Critical patent/CA3064567A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3064567A 2017-05-23 2018-05-23 A protein binding nkg2d, cd16 and a tumor-associated antigen Pending CA3064567A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201762510168P 2017-05-23 2017-05-23
US201762510167P 2017-05-23 2017-05-23
US201762510137P 2017-05-23 2017-05-23
US201762510169P 2017-05-23 2017-05-23
US62/510,167 2017-05-23
US62/510,169 2017-05-23
US62/510,137 2017-05-23
US62/510,168 2017-05-23
US201762539425P 2017-07-31 2017-07-31
US62/539,425 2017-07-31
PCT/US2018/034221 WO2018217945A1 (en) 2017-05-23 2018-05-23 A protein binding nkg2d, cd16 and a tumor-associated antigen

Publications (1)

Publication Number Publication Date
CA3064567A1 true CA3064567A1 (en) 2018-11-29

Family

ID=64395873

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3064567A Pending CA3064567A1 (en) 2017-05-23 2018-05-23 A protein binding nkg2d, cd16 and a tumor-associated antigen

Country Status (11)

Country Link
US (1) US20200157226A1 (enExample)
EP (1) EP3630181A4 (enExample)
JP (2) JP2020522474A (enExample)
KR (1) KR20200010429A (enExample)
CN (1) CN111278460A (enExample)
AU (1) AU2018273250A1 (enExample)
BR (1) BR112019024620A2 (enExample)
CA (1) CA3064567A1 (enExample)
IL (1) IL270801A (enExample)
MX (1) MX2019013995A (enExample)
WO (1) WO2018217945A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
CN112119093A (zh) 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CN113164570B (zh) 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
EP3941523A4 (en) 2019-03-22 2022-12-28 Mayo Foundation for Medical Education and Research MATERIALS AND METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
CN115708411A (zh) * 2020-04-16 2023-02-21 南通壹宸生物医药科技有限公司 一种pd-1突变体多肽及其制备和用途
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
JP2024537779A (ja) * 2021-09-29 2024-10-16 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及びｂａｆｆ－ｒに結合するタンパク質
US20230203202A1 (en) * 2021-12-08 2023-06-29 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
AU2023314795A1 (en) 2022-07-29 2025-03-06 Alector Llc Anti-gpnmb antibodies and methods of use thereof
EP4619023A1 (en) 2022-11-15 2025-09-24 Calico Life Sciences LLC Anti-papp-a antibodies and methods of use thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025166040A1 (en) 2024-01-31 2025-08-07 Alector Llc Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY33707A (es) * 2010-11-04 2012-05-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012125850A1 (en) * 2011-03-16 2012-09-20 Amgen Inc. Fc variants
BR112015006824A2 (pt) * 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
DE102013019352A1 (de) * 2013-11-13 2015-09-17 Elke Pogge Von Strandmann Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort
EP4050026A1 (en) * 2014-04-01 2022-08-31 Adimab, LLC Method of obtaining or identifying one or more common light chains for use in preparing a multispecific antibody
US10647768B2 (en) * 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
WO2016022939A1 (en) * 2014-08-08 2016-02-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for 5t4 and methods of their use
MX384198B (es) * 2014-12-19 2025-03-14 Chiome Bioscience Inc Proteina de fusion que comprende tres dominios de union a 5t4 y cd3.
WO2016122701A1 (en) * 2015-01-26 2016-08-04 Macrogenics, Inc. Anti-dr5 antibodies and molecules comprising dr5-binding domains thereof
CN107530424A (zh) * 2015-02-20 2018-01-02 俄亥俄州国家创新基金会 针对nkg2d和肿瘤相关抗原的二价抗体
JP6840682B2 (ja) * 2015-06-23 2021-03-10 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的抗原結合タンパク質
US20180327499A1 (en) * 2015-11-13 2018-11-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
US20200048347A1 (en) * 2016-09-01 2020-02-13 Immunomab, Inc. Bispecific antibodies
CN110944651A (zh) * 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途

Also Published As

Publication number Publication date
AU2018273250A1 (en) 2019-12-12
BR112019024620A2 (pt) 2020-06-23
US20200157226A1 (en) 2020-05-21
WO2018217945A1 (en) 2018-11-29
MX2019013995A (es) 2020-07-29
JP2023030174A (ja) 2023-03-07
EP3630181A1 (en) 2020-04-08
EP3630181A4 (en) 2021-03-17
CN111278460A (zh) 2020-06-12
IL270801A (en) 2020-01-30
JP2020522474A (ja) 2020-07-30
KR20200010429A (ko) 2020-01-30
RU2019142714A (ru) 2021-06-23
RU2019142714A3 (enExample) 2021-10-22

Similar Documents

Publication Publication Date Title
AU2018329937B2 (en) Proteins binding nkg2d, cd16 and nectin4
US20200157226A1 (en) Proteins binding nkg2d, cd16 and a tumor-associated antigen
US12378318B2 (en) Proteins binding NKG2D, CD16 and a tumor-associated antigen
US20200277384A1 (en) Proteins binding nkg2d, cd16, and c-type lectin-like molecule-1 (cll-1)
US20200157174A1 (en) Proteins binding nkg2d, cd16 and ror1 or ror2
US20240018266A1 (en) Proteins binding cd123, nkg2d and cd16
US20190375838A1 (en) Proteins binding bcma, nkg2d and cd16
CA3112990A1 (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
US20200165344A1 (en) Proteins binding nkg2d, cd16 and flt3
US20200157227A1 (en) Proteins binding nkg2d, cd16 and a tumor-associated antigen
CA3054078A1 (en) Proteins binding cd33, nkg2d and cd16
IL268755B1 (en) Proteins binding her2, nkg2d and cd16
US20200024353A1 (en) Proteins binding psma, nkg2d and cd16
CA3054081A1 (en) Proteins binding gd2, nkg2d and cd16

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220916